Nedocromil sodium ameliorates skin manifestations in a murine model of chronic graft-versus-host disease

Bone Marrow Transplantation

Volumn 19, Issue 8, 1997, Pages 823-828

  Levi Schaffer, F ^a,b   Goldenhersh, M A ^a   Segal, V ^a   Nagler, A ^a  

^a HEBREW UNIVERSITY   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

cGVHD; Degranulation; Fibrosis; Mast cells; Mice; Skin

Indexed keywords

COMPOUND 48-80; HISTAMINE RELEASE INHIBITOR; NEDOCROMIL SODIUM; TOLONIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; GRAFT VERSUS HOST REACTION; INTRAPERITONEAL DRUG ADMINISTRATION; MAST CELL; MOUSE; NONHUMAN; PERITONEUM MAST CELL; PRIORITY JOURNAL; SKIN FIBROSIS; SKIN MANIFESTATION; SUBCUTANEOUS FAT;

EID: 0030915845     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1700734     Document Type: Article

References (24)

1. Sullivan KM, Shulman HM, Storb R et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood 1981; 57: 267-276.
2. De Gast GC, Gratama JW, Ringden O, Gluckman E. The multifactorial etiology of graft-versus-host disease. Immunol Today 1987; 8: 209-212.
3. Janin-Mercier A, Saurai JH, Bourges M et al. The lichen planus-like and sclerotic phases of the graft-versus-host disease in man: an ultrastructural study of six cases. Acta Dermatovener (Stockholm) 1981; 61: 187-193.
4. Hawkins RA, Claman HN, Clark RAF, Steigerward JC. Increased dermal mast cell populations in progressive systemic sclerosis: a link in chronic fibrosis? Ann Intern Med 1985; 102: 182-186.
5. Sheppard MN, Harrison NK. Lung injury, inflammatory mediators and fibroblast activation in fibrosing alveolitis. Thorax 1992; 47: 1064-1074.
6. Goto T, Befus D, Low R, Bienenstock J. Mast cell heterogeneity and hyperplasia in bleomycin-induced pulmonary fibrosis of rats. Am Rev Resp Dis 1984; 130: 797-802.
7. Persinger MA, Le Page P, Simard JP, Parcer GH. Mast cell numbers in incisional wounds in rat skin as a function of distance, time and treatment. Br J Dermatol 1983; 108: 179-187.
8. Jaffe BD, Claman HN. Chronic graft-vs-host disease as a model for scleroderma. I Description of model system. Cell Immunol 1983; 77: 1-12.
9. Claman HN, Jaffee BD, Huff C, Clark RAF. Chronic graft-versus-host disease as a model for scleroderma. II Mast cell depletion with deposition of immunoglobulins in the skin and fibrosis. Cell Immunol 1985; 94: 73-84.
10. Claman HN, Lee Choi K, Sujansky W, Vatter AE. Mast cell 'disappearance' in chronic murine graft-vs-host disease (GVHD)-ultrastructural demonstration of 'phantom' mast cells. J Immunol 1986; 137: 2009-2013.
11. Levi-Schaffer F, Segal V, Meroki YA et al. Morphological evidence for chronic mast cell activation after prolonged exposure with supernatants from chronic graft-versus-host splenocytes. Immunol Lett 1991; 27: 13-18.
12. Riley PA, Amther ME, Klogh RW, Eady RP. Activity of nedocromil sodium in mast-cell-dependent reactions in rat. Int Arch Allergy Appl Immunol 1987; 82: 107-110.
13. Pearce FL, Al-Laith M, Bosman L et al. Effects of sodium cromoglycate and nedocromil sodium on histamine secretion from mast cells from various locations. Drugs 1989: 37 (Suppl 1): 37-43.
14. Jaffery G, Coleman YW, Huntley J, Bell EB. Mast cell recovery following chronic treatment with compound 48/80. Int Arch Allergy Appl Immunol 1994; 105: 274-280.
15. Levi-Schaffer F, Riesel N, Soffer D et al. Mast cell activity in experimental allergic encephalomyelitis. Mol Chem Neuropathol 1991; 15: 173-184.
16. Wingren W, Enerback L. Mucosal mast cells of the rat intestine: a re-evaluation of fixation and staining properties, with special reference to protein blocking and solubility of the granular glycosaminoglycan. Histochem J 1983; 15: 571-582.
17. Auty RM, Holgate ST. Nedocromil sodium: a review of its anti-inflammatory properties and clinical activity in the treatment of asthma. In: Kay AB (ed.). Allergy and Asthma. New Trends and Approaches to Therapy. Blackwell: Oxford, UK, 1989, pp 171-188.
18. Krüger G, Lagunoff D. Mast cell restoration. A study of the rat peritoneal mast cell after depletion with polymyxin B. Int Arch Allergy Appl Immunol 1981; 65: 278-290.
19. Levi-Schaffer F, Rubinchik E. Activated mast cells are fibrogenic for 3T3 fibroblasts. J Invest Dermatol 1995; 104: 999-1003.
20. Nagler A, Segal V, Slavin S, Levi-Schaffer F. Ketotifen therapy in chronic graft-vs-host disease (cGVHD): effect on mast cell activation. Clin Exp Immunol 1995; 100: 529-535.
21. Walker MA, Harley RA, Leroy EC. Inhibition of fibrosis in TSK mice by blocking mast cell degranulation. J Rheumatol 1987; 14: 229-230.
22. Walker M, Harley R, Leroy EC. Ketotifen prevents skin fibrosis in the tight skin mouse. J Rheumatol 1990; 17: 57-59.
23. Joseph M, Tsicopoulos A, Tonnel AB, Capron A. Modulation by nedocromil sodium of immunologic and non-immunologic activation of monocytes, macrophages and platelets. J All Clin Immunol 1993; 92: 165-270.
24. R) on the activation of human eosinophils and neutrophils and the release of histamine from mast cells. Allergy 1988; 43: 268-276.